Molecular Imaging & Therapy
Breast Cancer Imaging Trials
- (163-22) SSTR targeted imaging for patients with breast cancer.
- (182-20) Estrogen receptor-targeted imaging compared to standard-of-care Imaging in patients with breast cancer (Open to patients with newly diagnosed and suspected recurrence of estrogen receptor-positive breast cancer)
- (206-21) Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
- (207-21) A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Retifanlimab and Epacadostat
Myeloma Imaging Trial
Prostate Cancer Therapy Trials
- (114-20) Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
- (128-23) A Phase 4 Open–Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men With Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer
- (178-23) Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- (222-21) PSMA-targeted therapy for patients with prostate cancer (SPLASH).
- (232-21) PSMA-targeted therapy for patients with prostate cancer (ECLIPSE).
Neuroendocrine Targeted Therapy Trial
Other Cancer Types:
- (117-23) A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumors
- A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumors
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-557-0285